OC
PJP icon

Oppenheimer & Co’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Oppenheimer & Co’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,662
Closed -$213K – 1508
2024
Q1 		$213K Buy
+2,662
New +$206K ﹤0.01% 1316
2016
Q1 		– Sell
-6,977
Closed -$488K – 1301
2015
Q4 		$488K Buy
6,977
+165
+2% +$11.7K 0.01% 775
2015
Q3 		$452K Sell
6,812
-4,927
-42% -$383K 0.01% 849
2015
Q2 		$920K Buy
11,739
+1,121
+11% +$87.3K 0.03% 654
2015
Q1 		$811K Buy
10,618
+4,132
+64% +$304K 0.02% 700
2014
Q4 		$432K Sell
6,486
-7,084
-52% -$472K 0.01% 882
2014
Q3 		$864K Buy
13,570
+139
+1% +$8.58K 0.03% 650
2014
Q2 		$820K Sell
13,431
-1,238
-8% -$71.8K 0.02% 682
2014
Q1 		$831K Buy
14,669
+10,013
+215% +$569K 0.02% 672
2013
Q4 		$249K Sell
4,656
-2,115
-31% -$106K 0.01% 1106
2013
Q3 		$312K Buy
6,771
+932
+16% +$42.5K 0.01% 961
2013
Q2 		$247K Buy
+5,839
New +$243K 0.01% 1013

Other funds holding PJP

PAM
Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $445M AUM 31.98% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Oppenheimer & Co's PJP Position: Q2 2024 in Review

Oppenheimer & Co sold out of Invesco Pharmaceuticals ETF (PJP) in Q2 2024, closing a stake of 2,662 shares — an estimated $213K sold.

Oppenheimer & Co first reported a position in PJP in Q2 2013 and held it in 12 quarters. The position peaked at $920K in Q2 2015. 89 funds tracked by Wall St. Rank hold PJP as of Q2 2024.

  • Oppenheimer & Co reported no remaining Invesco Pharmaceuticals ETF position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 2,662 Invesco Pharmaceuticals ETF shares in Q2 2024, an estimated $213K.
  • Oppenheimer & Co first reported a position in Invesco Pharmaceuticals ETF in Q2 2013 and held it in 12 quarters.
  • Oppenheimer & Co's Invesco Pharmaceuticals ETF position peaked at $920K in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.